T1	Participants 229 274	patients with myelodysplastic syndromes (MDS)
T2	Participants 58 83	myelodysplastic disorders
T3	Participants 276 315	Sixty-eight evaluable patients with MDS
T4	Participants 1293 1310	patients with MDS
